Bluejay Diagnostics, Inc.

NasdaqCM BJDX

Bluejay Diagnostics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 88.66%

Bluejay Diagnostics, Inc. Gross Profit Margin is 88.66% for the Trailing 12 Months (TTM) ending September 30, 2024. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Bluejay Diagnostics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -58.30%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: BJDX

Bluejay Diagnostics, Inc.

CEO	Mr. Indranil Dey
IPO Date	Nov. 10, 2021
Location	United States
Headquarters	360 Massachusetts Avenue
Employees	10
Sector	Health Care
Industries Biotechnology Medical Instruments

Description

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Key trends

Past 5 years